145 related articles for article (PubMed ID: 17666334)
1. [Construction of whole-genome lamivudine-resistant hepatitis B virus mutant and its replication and expression in HepG2 cells].
Sun J; Wang C; Wen SJ; Wang ZH; Hou JL
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):991-3. PubMed ID: 17666334
[TBL] [Abstract][Full Text] [Related]
2. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
[TBL] [Abstract][Full Text] [Related]
3. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
4. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
[TBL] [Abstract][Full Text] [Related]
5. Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C.
Xu WZ; Fang Y; Li D; Wang Y; Shang QL; Li GQ; Teng X; Gu HX
World J Gastroenterol; 2008 Jun; 14(23):3733-8. PubMed ID: 18595141
[TBL] [Abstract][Full Text] [Related]
6. [Construction and biological activity assessment of core mutants of hepatitis B virus adr subtype].
Chen WH; Lin YL; Wang YJ; Luo KX
Di Yi Jun Yi Da Xue Xue Bao; 2002 Mar; 22(3):254-5. PubMed ID: 12390781
[TBL] [Abstract][Full Text] [Related]
7. RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells.
Ren JL; Pan JS; Cheng T; Dong J; Lu YP; Huang SJ; Shi HX; Wang L; Lian YM
Chin J Dig Dis; 2006; 7(4):230-6. PubMed ID: 17054586
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
9. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.
Lin CL; Liao LY; Wang CS; Chen PJ; Lai MY; Chen DS; Kao JH
Liver Int; 2004 Feb; 24(1):9-15. PubMed ID: 15101995
[TBL] [Abstract][Full Text] [Related]
10. The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
Ren GL; Fang Y; Ma HH; Lei YF; Wang D; Xu MC; Wang PZ; Huang CX; Nie OH; Sun YT; Bai XF
Antivir Ther; 2007; 12(6):865-76. PubMed ID: 17926641
[TBL] [Abstract][Full Text] [Related]
11. Differential inhibition of lamivudine-resistant hepatitis B virus by allele-specific RNAi.
Teng X; Xu WZ; Hao ML; Fang Y; Zhao YX; Chen SJ; Li D; Gu HX
J Virol Methods; 2010 Sep; 168(1-2):6-12. PubMed ID: 20403386
[TBL] [Abstract][Full Text] [Related]
12. [Transfection of siRNA expressing plasmids targeting S gene inhibits replication and expression of hepatitis B virus in hepatic cancer cells].
Bian ZQ; Cui ZL; Chen WZ; Liu MQ; Yan WY; Zheng ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(5):347-51. PubMed ID: 19563716
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
[TBL] [Abstract][Full Text] [Related]
14. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs.
Ding XR; Yang J; Sun DC; Lou SK; Wang SQ
Pharmacogenomics J; 2008 Feb; 8(1):61-70. PubMed ID: 17505500
[TBL] [Abstract][Full Text] [Related]
15. A novel hepatitis B virus variant S 129 (Gln-->Leu): lack of correlation between antigenicity and immunogenicity.
Wu L; He JW; Yao X; Li HM; Wen YM
J Med Virol; 1999 Dec; 59(4):424-30. PubMed ID: 10534722
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
Lai MW; Yeh CT
Antivir Ther; 2008; 13(7):875-9. PubMed ID: 19043921
[TBL] [Abstract][Full Text] [Related]
17. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR.
Punia P; Cane P; Teo CG; Saunders N
J Hepatol; 2004 Jun; 40(6):986-92. PubMed ID: 15158340
[TBL] [Abstract][Full Text] [Related]
20. [Long-fragment RNA inhibits hepatitis B virus gene replication and expression in HepG2.2.15 cells].
Tian L; He S; Li X; Hu WY; Peng PL; Wang F; Gao CY; Ren H; Tang KF
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):44-7. PubMed ID: 21272458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
